Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?
12:07pm, Tuesday, 16'th Dec 2025
The Dow Jones tracks 30 of the largest American companies across different sectors. Verizon, Chevron, and Merck hold the highest dividend yields in the Dow Jones.
3 Healthcare Giants Just Raised Dividends—Here's Who Pays the Most
09:17am, Tuesday, 16'th Dec 2025
Major players in healthcare are increasing their commitments to return capital to shareholders, resulting in significantly higher dividends. Recent dividend announcements from major companies in the
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
06:51pm, Monday, 15'th Dec 2025
The latest trading day saw Amgen (AMGN) settling at $325.31, representing a +2.38% change from its previous close.
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
10:25am, Monday, 15'th Dec 2025
Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.
Amgen Inc. $AMGN Shares Sold by Corient Private Wealth LLC
05:06am, Monday, 15'th Dec 2025
Corient Private Wealth LLC reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commiss
30,728 Shares in Amgen Inc. $AMGN Acquired by Caldwell Trust Co
03:52am, Monday, 15'th Dec 2025
Caldwell Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC
2 Dividend Stocks to Double Up on Right Now
02:47pm, Sunday, 14'th Dec 2025
These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue.
Why Ditching Schwab U.S. Dividend Equity ETF In the AI Era Is a Mistake
10:10am, Saturday, 13'th Dec 2025
The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in technology giants and growth-oriented investments. At the same time, dividend
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA® (inebilizumab-cdon) for the t
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
09:25am, Friday, 12'th Dec 2025
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
06:09pm, Thursday, 11'th Dec 2025
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG THOUSAND OAKS, Calif. , De
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
04:01pm, Tuesday, 09'th Dec 2025
THOUSAND OAKS, Calif. , Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026.
The Generational Shift I See Now - And My 33 Stocks For What's Coming
07:30am, Sunday, 07'th Dec 2025
I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and at
Amgen Inc. $AMGN Shares Bought by Cerity Partners LLC
04:21am, Sunday, 07'th Dec 2025
Cerity Partners LLC grew its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Comm
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
10:00am, Friday, 05'th Dec 2025
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
